Lupin’s generic psoriasis treatment approved by USFDA
29 December 2017 | News
Lupin has received final approval for its Calcipotriene Topical Solution, 0.005% (Scalp Solution) from the United States Food and Drug Administration (USFDA) to market a generic version of Dovonex Scalp Solution
Lupin Pharmaceuticals, Inc. is the U.S. wholly owned subsidiary of Lupin Limited, which is among the top five pharmaceutical companies in India.
Lupin is developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.
The company has received final approval from the US health regulator for its generic version of Dovonex scalp solution used in treatment of psoriasis of scalp.
The approval by the US Food and Drug Administration (USFDA) to Lupin's calcipotriene topical solution is for strength of 0.005 per cent (scalp solution.
It is the generic version of Dovonex scalp solution of Lep Pharmaceutical Products Ltd.
It is used for topical treatment of chronic, moderately severe psoriasis of the scalp.
Citing IMS data, the company said Calcipotriene topical solution had annual sales of USD 5.9 million in the US till October this year.
